Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxybutynin Transdermal System in Pediatric Detrusor Overactivity
NCT00224016Phase 4Completed
- Sponsor
- Watson Pharmaceuticals
- Start
- Dec 2004
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oxybutynin in neurogenic detrusor overactivity (NDO), sponsored by Watson Pharmaceuticals. Started Dec 2004; status: completed.
02
Drugs
oxybutynin
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT00224016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00224016.